20/20 Biolabs, Inc.
AIDX
$0.60
$0.011.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -2.17M | -1.31M | -825.50K | -802.80K | -764.60K |
| Total Depreciation and Amortization | 17.90K | 20.10K | 21.10K | 22.30K | 23.50K |
| Total Amortization of Deferred Charges | 240.40K | 97.90K | 17.20K | -- | -- |
| Total Other Non-Cash Items | 696.40K | 398.00K | 127.80K | 127.80K | 127.80K |
| Change in Net Operating Assets | -68.90K | 280.00K | 273.80K | 141.50K | 125.00K |
| Cash from Operations | -1.29M | -511.70K | -385.70K | -511.20K | -488.30K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -5.40K | -- | -- | -- | -- |
| Cash from Investing | -5.40K | -- | -- | -- | -- |
| Total Debt Issued | 250.00K | 411.90K | 506.60K | 35.00K | 70.00K |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 4.80K | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 5.00M | 0.00 | 0.00 | 96.20K | 192.30K |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -762.60K | -23.90K | -- | -- | -- |
| Cash from Financing | 4.49M | 392.80K | 506.60K | 131.20K | 262.30K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.19M | -118.90K | 120.90K | -380.00K | -226.00K |